Treace Medical Concepts, Inc. revised earnings guidance for the full-year 2024. The company now expected full-year 2024 revenue of $201 million to $211 million, representing growth of 7% to 13%, compared to full-year 2023. This compares to previous guidance of $220 million to $225 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.91 USD | -3.27% | +0.51% | -53.65% |
May. 29 | Treace Medical Concepts Insider Bought Shares Worth $253,475, According to a Recent SEC Filing | MT |
May. 17 | North American Morning Briefing : The "Everything -2- | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-53.65% | 366M | |
-24.88% | 7.32B | |
+7.04% | 6.66B | |
+15.10% | 5.5B | |
-15.87% | 4.88B | |
+14.96% | 4.1B | |
-21.42% | 3.89B | |
-25.03% | 2.83B | |
+44.01% | 2.31B | |
+1.98% | 2.07B |
- Stock Market
- Equities
- TMCI Stock
- News Treace Medical Concepts, Inc.
- Treace Medical Concepts, Inc. Revises Earnings Guidance for the Full-Year 2024